Zoetis Inc. A Stock
€157.88
Your prediction
Zoetis Inc. A Stock
Pros and Cons of Zoetis Inc. A in the next few years
Pros
Cons
Performance of Zoetis Inc. A vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Zoetis Inc. A | 1.480% | -0.205% | 1.065% | -7.503% | -12.497% | 10.380% | 71.249% |
| Pfizer Inc. | 0.060% | 0.929% | 5.696% | -25.726% | -0.115% | -19.871% | -24.241% |
| Elanco Animal Health Inc. | 0.310% | 30.943% | 14.794% | 90.106% | 19.379% | -40.266% | - |
| Biogen Inc. | 0.440% | 3.119% | 7.753% | -28.472% | -13.062% | -8.929% | 0.663% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When examining the financials of Zoetis (NYSE: ZTS), a leading company in the pharmaceutical industry, a preliminary review reveals a robust picture with consistent growth in total assets over the last three years. This growth is coupled with a stable increase in shareholder equity, indicating prudent financial management and a strong balance sheet foundation. A deeper dive into the detailed numbers should provide further insights into the organization's financial health, as well as potential areas of caution.
Growing Top Line: Zoetis has demonstrated a steady increase in total revenues, with the trailing twelve-month (TTM) revenue at approximately $8.37 billion. The year-over-year quarterly revenue growth of 7.4% signals a solid capacity for expanding their market presence and sales effectiveness.
EBITDA and Operating Margins: The EBITDA and operating margins are notable strengths, with a TTM EBITDA of around $3.47 billion and an operating margin of 37.1%. These numbers suggest efficient operational management and profitability.
Comments
News
Zoetis (ZTS) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q1 2024 Earnings CallMay 02, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Why Zoetis Stock Popped by Almost 6% on Thursday
Investors were meowing for animal healthcare specialist Zoetis (NYSE: ZTS) on Thursday, following the company's release of its latest quarterly results. These obviously pleased market participants
1 Magnificent Dividend Growth Stock That's Down 40% and Trading at a Once-in-a-Decade Valuation
So far, 2024 has been a year to forget for animal healthcare juggernaut Zoetis (NYSE: ZTS). Hit by the triple whammy of weak earnings, a formal investigation from the European Commission, and